From the January/February 2022 issue of HealthCare Business News magazine
"Hitachi's customers and provider partners will not experience a change in the way in which they are serviced," said Higuchi.
American Securities to acquire SimonMed for $600 million
American Securities has put forth $600 million in April to acquire radiology and imaging company SimonMed.
The hybrid practice consists of a large radiology group and 150 imaging centers. Both made the agreement in March and hope to close the deal by the end of April, according to private equity intelligence news resource, PE Hub.
Serving as both an outpatient diagnostic imaging provider and operator of its own radiology group, SimonMed employs 200 experienced subspecialty-trained radiologists across nine states, with its headquarters located in Scottsdale, Arizona.
It began exploring a possible sale back in January. Its auction attracted two other contenders, with the practice’s adjusted earnings tallied at $75 million before interest, taxes, depreciation and amortization. Lenders have been out with a loan in the last couple of weeks, which is structured as a club deal and led by JP Morgan Private Bank, reports PE Hub.
Its sale builds on American Securities’ healthcare portfolio, which already consists of North American Partners in Anesthesia, Aspen Dental, and Air Methods.
The acquisition is also considered to be a sign of further consolidation in healthcare, with other recent examples including six new partnerships established by Radiology Partners with practices providing services in California, Colorado, Idaho, Montana, Tennessee, Texas, Wisconsin and Wyoming; and Prestige Medical Imaging’s acquisition of G.E. Walker, a Southeast provider of radiology solutions and services.
American Securities declined to comment.
GE Healthcare acquires Zionexa
GE Healthcare acquired Zionexa in May with the intent to help develop and bring to market its pipeline biomarkers, including its recently FDA-approved PET imaging agent, Cerianna.
Also known as fluoroestradiol F-18, Cerianna is used as an adjunct to biopsy to detect estrogen receptor (ER)- positive lesions, and helps provide insights on which treatment plans may be best for a patient with recurrent or metastatic breast cancer. Currently available to a quarter of the relevant patient population, GE’s Pharmaceutical Diagnostics business plans to scale access to the tracer to a minimum of 75% of patients by 2023.
“This acquisition further demonstrates our commitment to enabling precision health and providing innovations that support oncologists, nuclear medicine specialists and other physicians throughout a cancer patient’s journey, from initial screening and diagnosis to informing therapy selection and monitoring the effectiveness of treatment,” said Kevin O’Neill, president and CEO of GE Healthcare Pharmaceutical Diagnostics, in a statement.
